Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14485165 | 0.84 | DDB1 (0.40) | KDM4ECYP19A1LMNA | |
| SCHEMBL576925 | 0.76 | KMT2A (0.41) | KDM4ETSHRKMT2ACYP19A1LMNA | |
| SCHEMBL6291805 | 0.73 | PLA2G6 (0.41) | TSHRKMT2A | |
| SCHEMBL577132 | 0.73 | KMT2A (0.41) | KDM4ETSHRKMT2ACYP19A1 | |
| SCHEMBL12679302 | 0.71 | TSHR (0.45) | KDM4ETSHRKMT2ATDP1CYP19A1 | |
| SCHEMBL28763117 | 0.69 | DDB1 (0.41) | KDM4ETSHRKMT2ACYP19A1ADORA3 | |
| SCHEMBL25608600 | 0.69 | PTGS2 (0.39) | KDM4ETSHRKMT2AL3MBTL1CYP19A1 | |
| SCHEMBL21937605 | 0.67 | DRD2 (0.41) | — | |
| SCHEMBL18227515 | 0.67 | CTRC (0.36) | L3MBTL1CYP19A1 | |
| SCHEMBL18227614 | 0.67 | CTRC (0.36) | TSHRKMT2ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| EP-1387829-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002090333-A1 | NOVEL PYRIDINONE AND RELATED HETEROCYCLIC DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186104-A1 | Novel pyridinone and related heterocyclic derivatives | CBR1, CBR3, CHRM1 | KDM4E 776/4885TSHR 1046/4885KMT2A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.